HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ad For Diorshow Is A No-Go; ASA Not Warming To Photoshopping

This article was originally published in The Rose Sheet

Executive Summary

U.K.’s Advertising Standards Authority advises LVMH Moët Hennessy-Louis Vuitton’s Parfums Christian Dior division to discontinue running an ad for Diorshow mascara that features actress Natalie Portman’s digitally enhanced eyelashes. ASA has warned industry in guidance about taking such liberties post-production that could inflate consumer expectations for product performance.

You may also be interested in...

L’Oreal Win In UK Ad Forum May Be Best Promotion For Maybelline Mascara

The UK’s Advertising Standards Authority accepts that L’Oreal’s Maybelline Total Temptation Mascara really does award the lashes seen in advertising without pre- or post-production enhancements. A complainant challenged a commercial for the product, convinced that the mascara’s effects were deceptively exaggerated.

ASA Chides Nivea For Retouching Mature Skin In Vital Ad

Nivea owner Beiersdorf defends post-production touch-ups to an older model in advertising for its Nivea Vital anti-aging cream, as the ad did not include quantifiable performance claims or a before-and-after visual comparison. The U.K.’s Advertising Standards Authority maintains the ad should not run again as formatted.

ASA, Transformulas Don’t See Eye To Eye On Anti-Aging Gel Claims

Transformulas’ use of “before” and “after” photographs to demonstrate the effect of its EyeLifting Gel was potentially misleading and should not be repeated in future ads, the U.K.-based Advertising Standards Authority says. The firm’s study data was also insubstantial to support efficacy claims, according to ASA.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts